Ketamine: Linking NMDA receptor hypofunction, gamma oscillations and psychosis (commentary on Qin et al., 2022)
European Journal of Neuroscience November 28, 2022 T. Reilly
Ketamine acts primarily through non-competitive NMDA receptor antagonism but has myriad downstream effects. Previously best known as an anaesthetic, analgesic or substance of abuse, it is now part of psychiatry’s toolkit as an anti-depressant (Price et al., 2022). Ketamine is also useful as a model of psychosis, reproducing symptoms and allowing examination of corresponding brain states. It was...